Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids

See allHide authors and affiliations

Science  07 Feb 2003:
Vol. 299, Issue 5608, pp. 893-896
DOI: 10.1126/science.1077215

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Chronic hepatitis B virus (HBV) infection is a major cause of liver disease. Only interferon-α and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy. However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors. Potent new antiviral compounds suitable for monotherapy or combination therapy are highly desired. We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity. These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.

  • * These authors contributed equally to this work.

  • To whom correspondence should be addressed. E-mail: karl.deres.kd1{at} (K.D.); c.schroeder{at}; arnold.paessens.ap{at} (A.P.);{at} (H.R.-W.)

View Full Text

Stay Connected to Science